Multiple Sclerosis Update

April 2008
PharmaWatch: CNS;Apr2008, Vol. 7 Issue 4, p7
Market Research Report
The article offers news briefs related to results of clinical trials for treatment of multiple sclerosis. BioMS Medical Corp. has revealed that the Data Safety Monitoring Board (DSMB) has recommended to the company to continue the trial for its MBP8298 drug. Likewise, Opexa Therapeutics Inc. has been urged by DSMB to continue the Phase II trial for Tovaxin. Sitris Pharmaceuticals Inc. has said that its drug candidate SRT501, when orally administered, suppressed neurological dysfunction.


Related Articles

  • Opexa reports additional positive data from Phase IIb multiple sclerosis study.  // PharmaWatch: CNS;Dec2008, Vol. 7 Issue 12, p9 

    The article reports on additional positive results from Opexa Therapeutics Inc.'s Phase IIb clinical trial for Tovaxin for the treatment of multiple sclerosis. The findings indicate that Tovaxin demonstrated a benefit across all clinical and magnetic resonance imaging endpoints in prospective...

  • Síntesis intratecal de IgGy permeabilidad de la barrera sangre-LCR en el seguimiento de pacientes con esclerosis múltiple tratados con biomodulina T. González-Quevedo Monteagudo, Alina; Alfaro Capdegelle, Ileana; Gámez Morales, Lorenzo Antonio; Fernández Carriera, Rebeca; Lara Rodríguez, Rosa F.; Rodríguez Martín, Román; Maza, Julia // Revista Mexicana de Neurociencia;ene/feb2007, Vol. 8 Issue 1, p18 

    Introduction: Multiple sclerosis (MS) has been treated with various immunomodulatory drugs, among which products derived from the thymus have been considered. In the present work the results of an open, controlled clinical trial, where the efficacy of biomoduline T (BT) on the clinical course of...

  • BioMS Medical: potential to broaden MS treatment options.  // PharmaWatch: CNS;Apr2007, Vol. 6 Issue 4, p4 

    The article reports on the move of BioMS Medical to initiate an open-label extension of its MAESTRO-01 pivotal phase II/III trial of MBP-8298 in patients with secondary progressive multiple sclerosis. It states that MAESTRO-02 was conducted in Canada and Europe and will provide additional...

  • Dirucotide Data Show 'Nice Signal' Despite Miss.  // Bioworld Week;2/9/2009, Vol. 17 Issue 6, p2 

    The article reports on the determination of BioMS Medical Corp. in Edmonton, Alberta, despite its dirucotide data failure. According to the article, the company fell down for about 30.3% due to its relapse rate failure to its Phase II study on patients with multiple sclerosis (MS). However, the...

  • Factors associated with the risk of secondary progression in multiple sclerosis. Koch, M.; Uyttenboogaart, M.; van Harten, A.; De Keyser, J. // Multiple Sclerosis (13524585);Jul2008, Vol. 14 Issue 6, p799 

    Objective To investigate factors associated with the risk of secondary progression in relapsing-remitting onset multiple sclerosis (MS). Methods We used Kaplan-Meier survival analyses and a multivariable Cox regression model to estimate the influence of the factors: gender, age at disease onset,...

  • Sanofi: Aubagio's tolerability profile is key differentiator in light of lackluster efficacy.  // PharmaWatch: CNS;Feb2012, Vol. 11 Issue 2, p4 

    The author discusses the Phase III trial results for Aubagio in the treatment of multiple sclerosis by Sanofi SA. The author mentions that the clinical trial aims to compare the safety, and tolerability of once-daily oral Aubagio to Rebif in patients with relapsing forms of multiple sclerosis....

  • MS Treatments Enter the Next Generation.  // Review of Optometry;12/15/2008 Part 1 of 2, Vol. 145 Issue 12, p48 

    The article provides information on various multiple sclerosis (MS) treatments in the U.S. It includes primary disease-modifying therapies such as Avonex, Betaseron and Copazone. Meanwhile, several other monoclonal antibody medications are in clinical trials as of 2008 including Alemtuzumab,...

  • New biologic offers hope for MS patients. LoBuono, Charlotte // Drug Topics;1/10/2005, Vol. 149 Issue 1, p17 

    The Food and Drug Administration (FDA) recently granted expedited approval for natalizumab to reduce the frequency of clinical exacerbations in those with the relapsing forms of multiple sclerosis (MS). The FDA granted expedited approval based on the first-year safety and efficacy data from two...

  • Genzyme and Bayer: alemtuzumab - miracle cure or another Tysabri?  // PharmaWatch: Biotechnology;Dec2008, Vol. 7 Issue 12, p4 

    The article reports on the result of the clinical trial of alemtuzumab. It states that results from the final three-year analysis of alemtuzumab demonstrate its potential in treating multiple sclerosis patients. It adds that results from the final three-year analysis of the 334-patient...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics